Nanohale AG (FYB) | WebDisclosure

Basculer en Français

8306	Companies
115302	Keywords
55586	Articles
62607	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 06/13/2024 at 15:35, 5 months 9 days ago

Formycon Announces AGM Results and Board Changes

Shareholders 2023 Financial Year Supervisory Board AGM Formycon
BRIEF

published on 06/13/2024 at 15:35, 5 months 9 days ago

Formycon annonce les résultats de l'AGA et les changements au conseil d'administration

Actionnaires Exercice 2023 Conseil De Surveillance AGA Formycon
PRESS RELEASE

published on 06/13/2024 at 15:30, 5 months 9 days ago

Formycon reports on the results of the Annual General Meeting
Formycon AG reports on the results of its Annual General Meeting, including approvals of agenda items, new Supervisory Board members, and election of new Chairman

Annual General Meeting Shareholders Supervisory Board Formycon AG Biosimilars
BRIEF

published on 06/13/2024 at 10:46, 5 months 9 days ago

First Berlin Equity Research Lowers Price Target for Formycon AG to €80

First Berlin Equity Research Buy Recommendation Formycon AG FYB202 Stelara
BRIEF

published on 06/13/2024 at 10:46, 5 months 9 days ago

First Berlin Equity Research abaisse son objectif de cours pour Formycon AG à 80 €

Formycon AG Recommandation D'achat FYB202 Première Recherche Sur Les Actions À Berlin Stelara
PRESS RELEASE

published on 06/13/2024 at 10:41, 5 months 9 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH reaffirms Buy recommendation for Formycon AG and lowers price target to €80 amid expected launch of lucrative biosimilar FYB202. Analyst Simon Scholes provides insights on Formycon's future prospects and market dynamics

Stock Market Analysis Buy Recommendation Formycon AG First Berlin Equity Research GmbH Biosimilar
BRIEF

published on 06/13/2024 at 07:36, 5 months 9 days ago

Formycon Starts Clinical Development for FYB206, a Keytruda Biosimilar

Clinical Trials Biosimilars Formycon FYB206 Keytruda
BRIEF

published on 06/13/2024 at 07:36, 5 months 9 days ago

Formycon démarre le développement clinique de FYB206, un biosimilaire de Keytruda

Essais Cliniques Formycon Biosimilaires FYB206 Keytruda
PRESS RELEASE

published on 06/13/2024 at 07:31, 5 months 9 days ago

Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
Formycon initiates clinical program for FYB206, a biosimilar candidate for Keytruda, targeting immuno-oncology. Phase I and III trials underway to assess safety, efficacy, and PK equivalence

Clinical Development Biosimilar Formycon FYB206 Keytruda
BRIEF

published on 05/15/2024 at 07:35, 6 months 7 days ago

MS Pharma Partners with Formycon for Commercialization of FYB203 in MENA

MENA Region MS Pharma Biosimilar Formycon FYB203

Accesswire

Published on 11/22/2024 at 15:15, 22 minutes ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Published on 11/22/2024 at 14:45, 52 minutes ago

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Published on 11/22/2024 at 14:30, 1 hour 7 minutes ago

Allied Universal Named Presenting Sponsor of 2024 Lott IMPACT Trophy Recognizing College Football's Defensive Best
Published on 11/22/2024 at 14:20, 1 hour 17 minutes ago

Plaintree Systems Inc. Announces Second Quarter Fiscal 2025 Results
Published on 11/22/2024 at 14:05, 1 hour 32 minutes ago

First Gas-To-Power Data Centre Connection

View all ACCESSWIRE

EQS Group

Published on 11/22/2024 at 15:27, 9 minutes ago

EQS-Adhoc: Eckert & Ziegler raises its forecast for the current financial year once again
Published on 11/22/2024 at 14:46, 50 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/22/2024 at 14:45, 51 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/22/2024 at 14:44, 52 minutes ago

Form 8.3 - The Vanguard Group, Inc.: AngloGold Ashanti plc
Published on 11/22/2024 at 14:43, 53 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Distribution Services plc

Les Echos

Published on 11/22/2024 at 14:35, 1 hour 1 minute ago

Communiqué de presse Thales
Published on 11/22/2024 at 14:35, 1 hour 1 minute ago

Thales Press release
Published on 11/21/2024 at 06:58, 1 day 8 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 8 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 8 hours ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille

View all LES ECHOS COMFI WIRE